• 1
    Cavalli LR,Singh B,Isaacs C,Dickson RB,Haddad BR. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer. Cancer Genet Cytogenet 2004; 149: 3843.
  • 2
    Clarke CL,Sandle J,Jones AA,Sofronis A,Patani NR,Lakhani SR. Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriers. Br J Cancer 2006; 95: 5159.
  • 3
    Deng G,Lu Y,Zlotnikov G,Thor AD,Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science (New York) 1996; 274: 20579.
  • 4
    Ellsworth DL,Ellsworth RE,Love B,Deyarmin B,Lubert SM,Mittal V,Shriver CD. Genomic patterns of allelic imbalance in disease free tissue adjacent to primary breast carcinomas. Breast Cancer Res Treat 2004; 88: 1319.
  • 5
    Lakhani SR,Chaggar R,Davies S,Jones C,Collins N,Odel C,Stratton MR,O'Hare MJ. Genetic alterations in “normal” luminal and myoepithelial cells of the breast. J Pathol 1999; 189: 496503.
  • 6
    Larson PS,de las Morenas A,Bennett SR,Cupples LA,Rosenberg CL. Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas. Am J Pathol 2002; 161: 28390.
  • 7
    Larson PS,de las Morenas A,Cupples LA,Huang K,Rosenberg CL. Genetically abnormal clones in histologically normal breast tissue. Am J Pathol 1998; 152: 15918.
  • 8
    Larson PS,Schlechter BL,de las Morenas A,Garber JE,Cupples LA,Rosenberg CL. Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues. J Clin Oncol 2005; 23: 86139.
  • 9
    Holst CR,Nuovo GJ,Esteller M,Chew K,Baylin SB,Herman JG,Tlsty TD. Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res 2003; 63: 1596601.
  • 10
    Yan PS,Venkataramu C,Ibrahim A,Liu JC,Shen RZ,Diaz NM,Centeno B,Weber F,Leu YW,Shapiro CL,Eng C,Yeatman TJ, et al. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 2006; 12: 662636.
  • 11
    Cianciulli AM,Pescatore B,Bovani R,Coletta AM,Gandolfo GM,Greco C,Botti C. Aneusomy of chromosomes 1 and 17 in normal tissue adjacent to breast carcinomas. Eur J Histochem 1997; 41( Suppl 2): 15960.
  • 12
    Steinarsdottir M,Jonasson JG,Vidarsson H,Juliusdottir H,Hauksdottir H,Ogmundsdottir HM. Cytogenetic changes in nonmalignant breast tissue. Genes Chromosomes Cancer 2004; 41: 4755.
  • 13
    Meeker AK,Hicks JL,Gabrielson E,Strauss WM,De Marzo AM,Argani P. Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am J Pathol 2004; 164: 92535.
  • 14
    van Roozendaal CE,Gillis AJ,Klijn JG,van Ooijen B,Claassen CJ,Eggermont AM,Henzen-Logmans SC,Oosterhuis JW,Foekens JA,Looijenga LH. Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures. FEBS Lett 1998; 437: 10711.
  • 15
    Khan SA,Sachdeva A,Naim S,Meguid MM,Marx W,Simon H,Halverson JD,Numann PJ. The normal breast epithelium of women with breast cancer displays an aberrant response to estradiol. Cancer Epidemiol Biomarkers Prev 1999; 8: 86772.
  • 16
    Widschwendter M,Berger J,Daxenbichler G,Muller-Holzner E,Widschwendter A,Mayr A,Marth C,Zeimet AG. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res 1997; 57: 415861.
  • 17
    Gauthier ML,Pickering CR,Miller CJ,Fordyce CA,Chew KL,Berman HK,Tlsty TD. p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue. Cancer Res 2005; 65: 17929.
  • 18
    Ding L,Erdmann C,Chinnaiyan AM,Merajver SD,Kleer CG. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res 2006; 66: 40959.
  • 19
    Botti C,Pescatore B,Mottolese M,Sciarretta F,Greco C,Di Filippo F,Gandolfo GM,Cavaliere F,Bovani R,Varanese A,Cianciulli AM. Incidence of chromosomes 1 and 17 aneusomy in breast cancer and adjacent tissue: an interphase cytogenetic study. J Am Coll Surg 2000; 190: 5309.
  • 20
    King C,Guo N,Frampton GM,Gerry NP,Lenburg ME,Rosenberg CL. Reliability and reproducibility of gene expression measurements using amplified RNA from laser-microdissected primary breast tissue with oligonucleotide arrays. J Mol Diagn 2005; 7: 5764.
  • 21
    Liu G,Loraine AE,Shigeta R,Cline M,Cheng J,Valmeekam V,Sun S,Kulp D,Siani-Rose MA. NetAffx: affymetrix probesets and annotations. Nucleic Acids Res 2003; 31: 826.
  • 22
    Baldi P,Long AD. A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics 2001; 17: 50919.
  • 23
    Carson JP,Zhang N,Frampton GM,Gerry NP,Lenburg ME,Christman MF. Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin. Cancer Res 2004; 64: 2096104.
  • 24
    Benjamini Y,Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57: 289300.
  • 25
    Tricarico C,Pinzani P,Bianchi S,Paglierani M,Distante V,Pazzagli M,Bustin SA,Orlando C. Quantitative real-time reverse transcription polymerase chain reaction: normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies. Anal Biochem 2002; 309: 293300.
  • 26
    Ashburner M,Ball CA,Blake JA,Botstein D,Butler H,Cherry JM,Davis AP,Dolinski K,Dwight SS,Eppig JT,Harris MA,Hill DP, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 259.
  • 27
    Lakhani SR,Van De Vijver MJ,Jacquemier J,Anderson TJ,Osin PP,McGuffog L,Easton DF. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor. HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20: 23108.
  • 28
    Grigoriadis A,Mackay A,Reis-Filho JS,Steele D,Iseli C,Stevenson BJ,Jongeneel CV,Valgeirsson H,Fenwick K,Iravani M,Leao M,Simpson AJ, et al. Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res 2006; 8: R56.
  • 29
    Sorlie T,Perou CM,Tibshirani R,Aas T,Geisler S,Johnsen H,Hastie T,Eisen MB,van de Rijn M,Jeffrey SS,Thorsen T,Quist H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 1086974.
  • 30
    Sorlie T,Tibshirani R,Parker J,Hastie T,Marron JS,Nobel A,Deng S,Johnsen H,Pesich R,Geisler S,Demeter J,Perou CM, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 841823.
  • 31
    Wang Y,Klijn JG,Zhang Y,Sieuwerts AM,Look MP,Yang F,Talantov D,Timmermans M,Meijer-van Gelder ME,Yu J,Jatkoe T,Berns EM, et al. Gene-expression profiles to predict distant metastasisof lymph-node-negative primary breast cancer. Lancet 2005; 365: 6719.
  • 32
    van de Vijver MJ,He YD,van't Veer LJ,Dai H,Hart AA,Voskuil DW,Schreiber GJ,Peterse JL,Roberts C,Marton MJ,Parrish M,Atsma D, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 19992009.
  • 33
    van 't Veer LJ,Dai H,van de Vijver MJ,He YD,Hart AA,Mao M,Peterse HL,van der Kooy K,Marton MJ,Witteveen AT,Schreiber GJ,Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 5306.
  • 34
    Chang HY,Sneddon JB,Alizadeh AA,Sood R,West RB,Montgomery K,Chi JT,van de Rijn M,Botstein D,Brown PO. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004; 2: E7.
  • 35
    Paik S,Shak S,Tang G,Kim C,Baker J,Cronin M,Baehner FL,Walker MG,Watson D,Park T,Hiller W,Fisher ER, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 281726.
  • 36
    Jones C,Mackay A,Grigoriadis A,Cossu A,Reis-Filho JS,Fulford L,Dexter T,Davies S,Bulmer K,Ford E,Parry S,Budroni M, et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 2004; 64: 303745.
  • 37
    Finak G,Sadekova S,Pepin F,Hallett M,Meterissian S,Halwani F,Khetani K,Souleimanova M,Zabolotny B,Omeroglu A,Park M. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res 2006; 8: R58.
  • 38
    Lee S,Medina D,Tsimelzon A,Mohsin SK,Mao S,Wu Y,Allred DC. Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am J Pathol 2007; 171: 25262.
  • 39
    Shen Q,Brown PH. Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia 2003; 8: 4573.
  • 40
    Dunn KL,Espino PS,Drobic B,He S,Davie JR. The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol 2005; 83: 114.
  • 41
    Janes PW,Daly RJ,deFazio A,Sutherland RL. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 1994; 9: 36018.
  • 42
    Creighton CJ,Hilger AM,Murthy S,Rae JM,Chinnaiyan AM,El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006; 66: 390311.
  • 43
    Shen Q,Brown PH. Transgenic mouse models for the prevention of breast cancer. Mutat Res 2005; 576: 93110.
  • 44
    Peto J,Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 2000; 26: 4114.
  • 45
    Antoniou AC,Pharoah PD,McMullan G,Day NE,Stratton MR,Peto J,Ponder BJ,Easton DF. A comprehensive model for familial breast cancer incorporating BRCA1. BRCA2 and other genes. Br J Cancer 2002; 86: 7683.
  • 46
    Iafrate AJ,Feuk L,Rivera MN,Listewnik ML,Donahoe PK,Qi Y,Scherer SW,Lee C. Detection of large-scale variation in the human genome. Nat Genet 2004; 36: 94951.
  • 47
    Sebat J,Lakshmi B,Troge J,Alexander J,Young J,Lundin P,Maner S,Massa H,Walker M,Chi M,Navin N,Lucito R, et al. Large-scale copy number polymorphism in the human genome. Science (New York) 2004; 305: 5258.
  • 48
    Tuzun E,Sharp AJ,Bailey JA,Kaul R,Morrison VA,Pertz LM,Haugen E,Hayden H,Albertson D,Pinkel D,Olson MV,Eichler EE. Fine-scale structural variation of the human genome. Nat Genet 2005; 37: 72732.
  • 49
    Stranger BE,Dermitzakis ET. The genetics of regulatory variation in the human genome. Hum Genomics 2005; 2: 12631.